Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 6/20 | 0.36 |
| ▸ | GRM2 | Q14416 | 3/20 | 0.36 |
| ▸ | GRM3 | Q14832 | 3/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.36 |
| ▸ | GRM8 | O00222 | 3/20 | 0.36 |
| ▸ | GRM6 | O15303 | 3/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | GRM5 | P41594 | 1/20 | 0.36 |
| ▸ | MTOR | P42345 | 1/20 | 0.36 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.36 |
| ▸ | PLCB1 | Q9NQ66 | 1/20 | 0.36 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.33 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4565810 | 1.00 | GRM4 (0.36) | GRM4GRM2GRM3CYP1A2CYP2C19 | |
| SCHEMBL4565617 | 0.93 | GRM4 (0.35) | GRM4GRM2GRM3CYP1A2CYP2C19 | |
| SCHEMBL4565712 | 0.93 | GRM4 (0.35) | GRM4GRM2GRM3CYP1A2CYP2C19 | |
| SCHEMBL2453547 | 0.93 | GRM4 (0.35) | GRM4GRM2GRM3CYP1A2CYP2C19 | |
| SCHEMBL8048516 | 0.79 | HDAC4 (0.33) | SLC1A2SLC1A1 | |
| SCHEMBL988351 | 0.74 | GRM4 (0.38) | GRM4GRM2GRM3CYP1A2CYP2C19 | |
| SCHEMBL3227341 | 0.74 | CYP1A2 (0.31) | CYP1A2 | |
| SCHEMBL8409821 | 0.74 | HDAC8 (0.36) | HSD11B1 | |
| Hydrochloric Acid SCHEMBL25405452 | 0.73 | GRM4 (0.36) | GRM4GRM2GRM3CYP1A2CYP2C19 | |
| SCHEMBL7439240 | 0.73 | CYP1A2 (0.37) | CYP1A2CYP2C19LMNAMTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090325889-A1 | HEPATITIS C SERINE PROTEASE INHIBITORS AND USES THEREFOR | CAMPBELL DAVID ALAN | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325889-A1 | HEPATITIS C SERINE PROTEASE INHIBITORS AND USES THEREFOR | PREP, HPN, PRSS1 | GRM4 4683/4885GRM2 4827/4885GRM3 4455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.